Skip to main content

Table 1 Hydroxyproline:proline ratio by treatment group and organ in the TGF-β/CTGF synergy model

From: Cooperative interaction of CTGF and TGF-β in animal models of fibrotic disease

Organ

Control

Treatments

 

-

TGF-β2

-

TGF-β2

TGF-β2

 

-

-

CTGF

CTGF

CTGF

 

-

-

-

-

FG-3019

Kidney

0.057 ± 0.001

0.061 ± 0.002

0.059 ± 0.001

0.094 ± 0.0051

0.085 ± 0.0031,3

Liver

0.015 ± 0.001

0.017 ± 0.001

0.016 ± 0.002

0.039 ± 0.0031

0.032 ± 0.0021,4

Lung

0.079 ± 0.002

0.078 ± 0.002

0.083 ± 0.001

0.088 ± 0.0012

0.083 ± 0.002,3

Heart

0.041 ± 0.001

0.044 ± 0.002

0.046 ± 0.002

0.055 ± 0.0021

0.053 ± 0.0031

  1. Data shown represent mean ± SEM, n = 6 to 10.
  2. 1P < 0.001, 2P < 0.01 compared with healthy control group, one way analysis of variance, Fisher's least significant difference.
  3. 3P < 0.05, 4P < 0.01 compared with transforming growth factor (TGF)-β2 and connective tissue growth factor (CTGF) coadministration group.